• Retrospective• 89 (42.8%) had methylated MGMT promoter,• The status of IDH1 in a cohort was wild type (patients diagnosed between 2016 and 2021)• No data on steroid use• Multivariate analysis adjusted for age, tumor location, extent of resection, KPS, radiochemotherapy, MGMT promoter methylation, and different blood cell counts and ratios. This evidence concerns the gene IDH1 and neoplasm.